AUSTIN, Texas, Aug. 5 /PRNewswire-FirstCall/ -- Introgen Therapeutics,
Inc. (Nasdaq: INGN), a leading developer of biopharmaceutical products for the
treatment of cancer and other diseases, will hold its quarterly conference
call to discuss second quarter results on Tuesday, August 9, 2005, at
4:30 p.m. Eastern Time (3:30 p.m. Central Time).
This call is being webcast by Thomson/CCBN and can be accessed at
Introgen's Web site at http://www.introgen.com .
The webcast is also being distributed through the Thomson StreetEvents
Network to both institutional and individual investors. Individual investors
can listen to the call at http://www.fulldisclosure.com , Thomson/CCBN's
individual investor portal, powered by StreetEvents. Institutional investors
can access the call via Thomson's password-protected event management site,
StreetEvents (http://www.streetevents.com ).
About Introgen Therapeutics, Inc.
Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of targeted molecular therapies
for the treatment of cancer and other diseases. Introgen is developing
molecular therapeutics, immunotherapies, vaccines and nano-particle tumor
suppressor therapies to treat a wide range of cancers using non-integrating
tumor suppressors, cytokines and genes. Introgen maintains integrated
research, development, manufacturing, clinical and regulatory departments and
operates multiple manufacturing facilities including a commercial scale cGMP
(512) 708-9310 Ext. 322
SOURCE Introgen Therapeutics, Inc.